Epirubicin extravasation: consequences of delayed management
- 6 January 2017
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2017
Abstract
Epirubicin is an anthracycline chemotherapy agent used for treatment of several cancers including oesophageal, breast and gastric. Extravasation is a well-recognised and serious complication of any intravenous therapies but especially chemotherapeutic agents. Signs of the injury can be subtle and without prompt recognition and treatment there can be extensive tissue damage and depending on location of injury this can result in significant functional loss. In this article, a case of delayed management of epirubicin extravasation from a cannula situated at the dorsum of the hand is discussed. Successful surgical reconstruction of the resulting substantial tissue damage using a radial forearm flap 21 days following injury is described.Keywords
This publication has 9 references indexed in Scilit:
- Overview, prevention and management of chemotherapy extravasationWorld Journal of Clinical Oncology, 2016
- Extravasation Injuries in AdultsISRN Dermatology, 2013
- Management of chemotherapy extravasation: ESMO–EONS Clinical Practice GuidelinesAnnals of Oncology, 2012
- Extravasation of Antineoplastic Agents: Prevention And TreatmentsPediatric Reports, 2012
- Extravasation injuries and accidental intra-arterial injectionContinuing Education in Anaesthesia Critical Care & Pain, 2010
- Extravasation of EpirubicinNew England Journal of Medicine, 2009
- Anthracycline extravasation injuries: management with dexrazoxaneTherapeutics and Clinical Risk Management, 2009
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Surgical Management after Doxorubicin and Epirubicin ExtravasationJournal of Hand Surgery (European Volume), 1998